β2M is a well-recognized prognostic biomarker in various B-cell malignancies, including DLBCL, HL, FL, MM, and CLL, and it is even recommended by the International Staging System for stratifying MM patients (10–18). The gene discussed is B2M; the disease is Hodgkins lymphoma.